Liraglutide

Osteoarthritis, Hip

Boston Medical Centerprotein_peptideN/AActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

5 Active assets in the Osteoarthritis, Hip cohort.

Asset / Sponsor	Phase	Rating
Dfn-15 Pfizer	Phase 4	BB
Intravenous Dexamethsone Poznan University of Medical Sciences	Phase 4	BB
Oxycodone Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	BB
HYDROMORPHONE HYDROCHLORIDE CII	Phase 3	BB
Tanezumab Pfizer	Phase 3	BB

View all 16 →

Same molecule, other indications

Liraglutide is also rated in:

metabolic diseaseDormant

A

Indicative ·

84 / 100

polycystic ovary syndromeDormant

BBB

Indicative ·

79 / 100

type 2 diabetes mellitusDormant

BBB

Indicative ·

79 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.